Pranlukast CAS 103177-37-3

What is Pranlukast CAS 103177-37-3?

Pranlukast CAS 103177-37-3 is a synthetic therapeutic agent originally introduced in Japan as a respiratory drug for chronic asthma and other allergic conditions; unlike bronchodilators that act directly on airway smooth muscle, it works by modulating inflammatory mediator pathways (specifically cysteinyl leukotriene signaling) to reduce bronchoconstriction, eosinophil infiltration, and airway hyperresponsiveness, and has also been evaluated clinically for allergic rhinitis, pediatric asthma, pruritus in dialysis patients, and suggested for other inflammatory disorders.

Specification

Feature

• Selective antagonist: Pranlukast selectively blocks cysteinyl leukotriene receptors (especially CysLT₁), targeting a key inflammatory pathway in asthma.
• Inflammation modulator: Acts on leukotriene-mediated inflammatory signaling rather than directly relaxing airway smooth muscle.
• Oral maintenance agent: Designed for oral administration with sustained action to support chronic management of respiratory disease.
• Research reagent: Used as a reference antagonist in pharmacological research on leukotriene receptor biology and related immune signaling systems.

Application

• Asthma therapy: Prescribed as maintenance treatment in mild to moderate chronic asthma to reduce bronchoconstriction and improve expiratory flow by antagonizing leukotriene signaling.
• Allergic rhinitis care: Evaluated in clinical studies for managing perennial allergic rhinitis by reducing inflammatory mediator effects in nasal tissues.
• Pediatric asthma: Investigated as a treatment option in pediatric patients with asthma to control symptoms and inflammation.
• Pruritus management: Studied for alleviating cutaneous itching in dialysis patients through modulation of leukotriene pathways.
• Inflammation research: Applied in laboratory and preclinical studies to investigate leukotriene receptor function, inflammatory signaling, and potential new therapeutic strategies in respiratory and systemic inflammation.

Packaging

Mikem offers flexible packaging options, including 25 kg of fiber drums for liquid products and 15–25 kg PP/PE bags for powder products, all customizable to meet your specific needs.